Rosebud Biosciences

What Rosebud Biosciences does

Rosebud Biosciences is an early-stage biotech company founded in 2020 and based in the San Francisco Bay Area that develops organoid-based drug discovery and safety assessment tools for rare genetic diseases in children. The company's core platform uses micropatterned circular "2.5D" organoids differentiated from patient-specific human induced pluripotent stem cells (hiPSCs), incorporating cells from multiple lineages (embryonic germ layers, endothelial, smooth muscle, fibroblasts) without requiring complex biopolymer matrices or specialized tissue culture plates. The platform is organized into tissue-specific modules — cardiac, hepatic, and neural organoids are currently available, with kidney organoids in development — and supports screening of small molecules, RNA therapies (ASOs, siRNAs), CRISPR and gene therapies, and immunotherapies.

The company's technology stack combines wet-lab organoid generation with robotics and machine learning, enabling simultaneous longitudinal monitoring of up to 10,000 patient-specific organoids via live-cell brightfield microscopy, complemented by biomarker assays (immunostaining, ELISAs, calcium assays). Rosebud's go-to-market is enterprise and partnership-focused, targeting pharmaceutical companies and rare disease researchers through direct outreach, industry conferences, and a strategic distribution partnership with iXCells Biotechnologies (announced January 2026) that integrates the organoid platform into iXCells' iPSC solutions channel. Revenue is expected to derive from licensing/co-development arrangements and contract research services, though no revenue, pricing, or contract values are publicly disclosed. The three-person team is led by a Stanford/Duke-trained physician-scientist CEO and a UC Berkeley-trained CTO with deep microscopy and ML expertise, backed by Y Combinator and the NSF Seed Fund.

Name

Rosebud Biosciences

Legal name

Rosebud Biosciences Inc.

Website

https://rosebudbiosci.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Rosebud Biosciences is a San Francisco-based early-stage biotech that builds patient-specific hiPSC-derived 2.5D organoid platforms to model rare genetic diseases in children and screen drug candidates. It serves pharmaceutical companies and rare disease researchers through direct partnerships and a strategic distribution alliance with iXCells Biotechnologies.

Ownership category

akta.pro rank

Product category

Organoid-based Drug Discovery Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

akta.pro secondary industries

Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA), Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Organoid drug discovery
• Rare disease therapeutics
• HiPSC disease modeling
• AI-driven drug screening
• Organoid platform services

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Organoid Platform Licensing / Co-development: Revenue is expected to come from strategic partnerships with pharmaceutical companies where Rosebud's organoid platform is used to model specific genetic diseases and screen drug candidates. Partnership structure with iXCells demonstrates a co-development model combining their respective capabilities.
2. Contract Research Services (Drug Screening): The company provides organoid-based drug discovery and safety assessment services to pharma partners, likely on a contract basis for specific therapeutic programs in heart, liver, neural, or kidney disease.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Rosebud Biosciences develops a proprietary 2.5D circular hiPSC-derived organoid platform that models pediatric rare genetic diseases by replicating patient-specific genetic mutations in a 100% human biological system. The platform combines longitudinal live-cell brightfield microscopy, biomarker assays, robotics, and machine learning to simultaneously monitor up to 10,000 patient-specific organoids for disease progression and drug response. The company partners with pharmaceutical companies and contractually screens drug candidates (small molecules, ASOs, siRNAs, CRISPR/gene therapies, immunotherapies) across cardiac, hepatic, neural, and renal organoid modules.

Product overview

Rosebud Biosciences operates as a single unified platform for rare genetic disease drug discovery. The company's core offering is its AI-driven Organoid Platform, which generates mutation-specific human induced pluripotent stem cell (hiPSC)-derived organoids for therapeutic screening. The platform is organized into product-specific organoid modules—Cardiac Organoids, Hepatic Organoids, and Neural Organoids (available), plus Kidney Organoids (in development)—each targeting specific tissue types for disease modeling and drug toxicity assessment. The integrated workflow combines robotics, machine learning, and longitudinal imaging to screen up to 10,000 patient-specific organoids simultaneously, enabling earlier prediction of human-specific safety and therapeutic response.

Differentiator

Problem solved

Functional benefit

Products and services

• hiPSC-Derived Organoid Platform A proprietary 2.5D circular organoid platform generated from disease-specific human induced pluripotent stem cells (hiPSCs) for rare genetic disease drug discovery and safety assessment. The platform is differentiated without complex biopolymer matrices or specialized tissue culture plates, supports screening of small molecules, RNA therapies, CRISPR and gene therapies, and immunotherapies, and is offered to pharmaceutical and biotech drug developers for cardiac, hepatic, neural, and renal therapeutic programs.

Quantifiable outcome

• Only 5% of rare genetic diseases have approved treatments — Rosebud aims to develop cures for the remaining 95%
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

One partnership is on record.

• iXCells BiotechnologiescoreStrategic or Co-development Partner · 28 January 2026iXCells Biotechnologies and Rosebud Biosciences announced a strategic partnership to integrate Rosebud's organoid generation and characterization capabilities into iXCells' existing iPSC solutions platform. The combined workflow merges iXCells' scalable iPSCore platform with Rosebud's AI-driven organoid technology to provide researchers with more biologically representative 3D model systems for drug discovery and safety assessment. The companies specifically highlighted applications in rare diseases, where earlier prediction of human-specific safety and therapeutic response can significantly impact development timelines and patient outcomes.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Ncardia: Specializes in iPSC-derived cardiac and neural cell models for drug discovery and safety assessment. Direct competitor in cardiac and neural organoid/cell-based disease modeling with shared pharma customer base.
• iXCells Biotechnologies: iPSC-focused cell biology services company with established pharma customer relationships and Rosebud's announced strategic partner. Most comparable in iPSC-based disease modeling and primary target customer base of pharma/biotech researchers.
• InSphero: Provides 3D organoid and spheroid models for drug discovery and safety testing across liver, pancreas, and other tissues. Directly comparable service offering for pharma partners needing scalable, human-relevant in vitro models.
• Mimetas: Develops Organ-on-Chip and 3D tissue models for drug discovery and toxicology. Direct competitor in organoid-based disease modeling for pharma with overlapping applications in cardiotoxicity, hepatotoxicity, and neurotoxicity screening.
• Emulate Inc. Commercializes Organ-on-Chip and organoid technology for drug development and safety assessment. Directly competes in providing human-relevant in vitro disease models to pharma, with comparable target customer base and application areas.

Emerging players

• Definium Biosciences: Early-stage organoid-based drug discovery company with comparable focus on scalable disease modeling. Emerging player with overlapping scientific approach to organoid-based drug screening and similar early-stage positioning.

Broad incumbents

• Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput biology with machine learning at scale. Highly comparable in its use of robotics, imaging, and ML to phenotype cellular models, though broader in scope than Rosebud's organoid focus.
• Insitro: Machine learning-driven drug discovery company using iPSC-derived cellular models and high-throughput data generation. Directly comparable in combining hiPSC biology with ML for therapeutic discovery, though operating at substantially larger scale and capital base.
• Hubrecht Organoid Technology (HUB): Pioneer in organoid technology with broad portfolio of disease-specific organoid models and established pharma partnerships. Established incumbent in the organoid space that competes for similar pharma service contracts.
• Cellular Dynamics International (Fujifilm): Major commercial supplier of iPSC-derived cell types and tissues for research and drug discovery. Provides foundational iPSC tools that overlap with Rosebud's disease modeling applications, though at much larger scale under Fujifilm ownership.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/rosebudbiosci
• LinkedInlinkedin.com/company/rosebud-biosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rosebud Biosciences